Assessment of the Utility of PAX8 Immunohistochemical Stain in Diagnosing Endocervical Glandular Lesions

Li Liang, Wenxin - Zheng, Jinsong Liu, Sharon X. Liang

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Context.-PAX8, a member of the paired-box family of genes, is expressed in many tumors of M ullerian origin. However, it is unclear whether PAX8 is a useful marker in diagnosing endocervical glandular lesions because of limited data. Objective.-To study the expression of PAX8 in endocervical glandular lesions. Design.-We first studied a cohort of 29 cervical cone biopsies, followed by a second cohort of 17 cases of endocervical adenocarcinoma and 20 cases of uterine endometrioid adenocarcinoma. Results.-In the first cohort, we found that PAX8 was expressed in 23 of 23 (100%) benign endocervical glandular epithelium, 15 of 16 (94%) adenocarcinoma in situ, and 21 of 26 (81%) invasive endocervical adenocarcinoma specimens. In the second cohort, endocervical adenocarcinomas were positive for PAX8 in 14 of 17 (82%), strongly and diffusely positive for p16 in 14 of 17 (82%), positive for carcinoembryonic antigen in 12 of 17 (71%), positive for vimentin in 2 of 17 (12%), and positive for estrogen receptor in 7 of 17 cases (41%). Uterine endometrioid cancer was positive for PAX8 in 20 of 20 (100%), weakly and/or patchy positive for p16 in 17 of 20 (85%), positive for carcinoembryonic antigen in 2 of 20 (10%), positive for vimentin in 19 of 20 (95%), and positive for estrogen receptor in 20 of 20 cases (100%). Conclusions.-PAX8 is expressed in the majority of benign, premalignant, and malignant endocervical glandular lesions. The usefulness of PAX8 in differentiating endocervical from endometrial lesions is limited.

Original languageEnglish (US)
Pages (from-to)148-152
Number of pages5
JournalArchives of Pathology and Laboratory Medicine
Volume140
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Adenocarcinoma
Coloring Agents
Carcinoembryonic Antigen
Vimentin
Estrogen Receptors
Endometrioid Carcinoma
Uterine Neoplasms
Epithelium
Biopsy
Genes
Neoplasms
Adenocarcinoma in Situ

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Assessment of the Utility of PAX8 Immunohistochemical Stain in Diagnosing Endocervical Glandular Lesions. / Liang, Li; Zheng, Wenxin -; Liu, Jinsong; Liang, Sharon X.

In: Archives of Pathology and Laboratory Medicine, Vol. 140, No. 2, 01.02.2016, p. 148-152.

Research output: Contribution to journalArticle

@article{bfa1fd5a801e4870adb14a98d6c90083,
title = "Assessment of the Utility of PAX8 Immunohistochemical Stain in Diagnosing Endocervical Glandular Lesions",
abstract = "Context.-PAX8, a member of the paired-box family of genes, is expressed in many tumors of M ullerian origin. However, it is unclear whether PAX8 is a useful marker in diagnosing endocervical glandular lesions because of limited data. Objective.-To study the expression of PAX8 in endocervical glandular lesions. Design.-We first studied a cohort of 29 cervical cone biopsies, followed by a second cohort of 17 cases of endocervical adenocarcinoma and 20 cases of uterine endometrioid adenocarcinoma. Results.-In the first cohort, we found that PAX8 was expressed in 23 of 23 (100{\%}) benign endocervical glandular epithelium, 15 of 16 (94{\%}) adenocarcinoma in situ, and 21 of 26 (81{\%}) invasive endocervical adenocarcinoma specimens. In the second cohort, endocervical adenocarcinomas were positive for PAX8 in 14 of 17 (82{\%}), strongly and diffusely positive for p16 in 14 of 17 (82{\%}), positive for carcinoembryonic antigen in 12 of 17 (71{\%}), positive for vimentin in 2 of 17 (12{\%}), and positive for estrogen receptor in 7 of 17 cases (41{\%}). Uterine endometrioid cancer was positive for PAX8 in 20 of 20 (100{\%}), weakly and/or patchy positive for p16 in 17 of 20 (85{\%}), positive for carcinoembryonic antigen in 2 of 20 (10{\%}), positive for vimentin in 19 of 20 (95{\%}), and positive for estrogen receptor in 20 of 20 cases (100{\%}). Conclusions.-PAX8 is expressed in the majority of benign, premalignant, and malignant endocervical glandular lesions. The usefulness of PAX8 in differentiating endocervical from endometrial lesions is limited.",
author = "Li Liang and Zheng, {Wenxin -} and Jinsong Liu and Liang, {Sharon X.}",
year = "2016",
month = "2",
day = "1",
doi = "10.5858/arpa.2015-0081-OA",
language = "English (US)",
volume = "140",
pages = "148--152",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "2",

}

TY - JOUR

T1 - Assessment of the Utility of PAX8 Immunohistochemical Stain in Diagnosing Endocervical Glandular Lesions

AU - Liang, Li

AU - Zheng, Wenxin -

AU - Liu, Jinsong

AU - Liang, Sharon X.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Context.-PAX8, a member of the paired-box family of genes, is expressed in many tumors of M ullerian origin. However, it is unclear whether PAX8 is a useful marker in diagnosing endocervical glandular lesions because of limited data. Objective.-To study the expression of PAX8 in endocervical glandular lesions. Design.-We first studied a cohort of 29 cervical cone biopsies, followed by a second cohort of 17 cases of endocervical adenocarcinoma and 20 cases of uterine endometrioid adenocarcinoma. Results.-In the first cohort, we found that PAX8 was expressed in 23 of 23 (100%) benign endocervical glandular epithelium, 15 of 16 (94%) adenocarcinoma in situ, and 21 of 26 (81%) invasive endocervical adenocarcinoma specimens. In the second cohort, endocervical adenocarcinomas were positive for PAX8 in 14 of 17 (82%), strongly and diffusely positive for p16 in 14 of 17 (82%), positive for carcinoembryonic antigen in 12 of 17 (71%), positive for vimentin in 2 of 17 (12%), and positive for estrogen receptor in 7 of 17 cases (41%). Uterine endometrioid cancer was positive for PAX8 in 20 of 20 (100%), weakly and/or patchy positive for p16 in 17 of 20 (85%), positive for carcinoembryonic antigen in 2 of 20 (10%), positive for vimentin in 19 of 20 (95%), and positive for estrogen receptor in 20 of 20 cases (100%). Conclusions.-PAX8 is expressed in the majority of benign, premalignant, and malignant endocervical glandular lesions. The usefulness of PAX8 in differentiating endocervical from endometrial lesions is limited.

AB - Context.-PAX8, a member of the paired-box family of genes, is expressed in many tumors of M ullerian origin. However, it is unclear whether PAX8 is a useful marker in diagnosing endocervical glandular lesions because of limited data. Objective.-To study the expression of PAX8 in endocervical glandular lesions. Design.-We first studied a cohort of 29 cervical cone biopsies, followed by a second cohort of 17 cases of endocervical adenocarcinoma and 20 cases of uterine endometrioid adenocarcinoma. Results.-In the first cohort, we found that PAX8 was expressed in 23 of 23 (100%) benign endocervical glandular epithelium, 15 of 16 (94%) adenocarcinoma in situ, and 21 of 26 (81%) invasive endocervical adenocarcinoma specimens. In the second cohort, endocervical adenocarcinomas were positive for PAX8 in 14 of 17 (82%), strongly and diffusely positive for p16 in 14 of 17 (82%), positive for carcinoembryonic antigen in 12 of 17 (71%), positive for vimentin in 2 of 17 (12%), and positive for estrogen receptor in 7 of 17 cases (41%). Uterine endometrioid cancer was positive for PAX8 in 20 of 20 (100%), weakly and/or patchy positive for p16 in 17 of 20 (85%), positive for carcinoembryonic antigen in 2 of 20 (10%), positive for vimentin in 19 of 20 (95%), and positive for estrogen receptor in 20 of 20 cases (100%). Conclusions.-PAX8 is expressed in the majority of benign, premalignant, and malignant endocervical glandular lesions. The usefulness of PAX8 in differentiating endocervical from endometrial lesions is limited.

UR - http://www.scopus.com/inward/record.url?scp=84957932381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957932381&partnerID=8YFLogxK

U2 - 10.5858/arpa.2015-0081-OA

DO - 10.5858/arpa.2015-0081-OA

M3 - Article

C2 - 26910219

AN - SCOPUS:84957932381

VL - 140

SP - 148

EP - 152

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 2

ER -